Press Release
September 22, 2023

Aditum Bio Announces Formation of Celexor Bio, Focused on Cell Depletion of Pathologic Cells in Autoimmune and Inflammatory Disorders

The Life Sciences team advised Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals.

Celexor Bio is being formed in connection with the in-licensing of a depleting antibody targeting immunoglobulin-like transcript 7 (ILT7), a highly specific cell surface marker found on plasmacytoid dendritic cells (pDCs), which is anticipated to close later this month. The compound (IMG-018) is being licensed from Inmagene Biopharmaceuticals and will be renamed CLXR-901.

Aditum Bio is committed to improving public health by accelerating R&D in disease areas with both large and more targeted patient populations, where medical innovation can have a significant impact.

The Goodwin team was led by Kingsley Taft and Rachael Bushey, and included Christopher Zhong.

For more details, read the press release and coverage in Endpoints News.